TransMedics Group, Inc. (TMDX) - Stock Analysis
Last updated: Jan 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Margin improvement ⢠Elevated debt TMDX shows markedly stronger near-term profitability and liquidity (quarterly gross margin 59%, EBITDA margin 24%, net margin 17%, cash $466.7M, positive FCF) but still carries high absolute debt and a demanding valuation that tempers the upside.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Support holding ⢠Overbought risk Support Level: $126â$130 Resistance Level: $140â$143 Over the last month TMDX has rallied from about $126 to $143, holding support near $126â$130 while testing resistance around $140â$143, so monitor for short-term overextension if it can't sustain above $140â142.
Sentiment & News
Key News Insights: ⢠OCS momentum ⢠Analyst optimism ⢠HQ expansion TransMedics enters 2026 with strong Q3 results, growing institutional support and analyst optimism around its OCS transplant platform and HQ expansion, though margin risks and possible 2026 momentum slowdown warrant caution.
AI Summary
TMDX has shifted from a binary clinical story to an execution-and-cash-generation investment where sustained quarterly FCF, normalized capex and margin expansion (versus refinancing/leverage risk) will determine whether its lofty multiples are justifiedâmonitor quarterly FCF/capex guidance, debt maturities/refinancing terms, and ENHANCE/DENOVO enrollment as the primary triggers.
Description
TransMedics Group is a commercial-stage medical technology company that develops and commercializes portable systems for perfusion, preservation and monitoring of donor organs to support transplantation in the U.S. and abroad. Its Organ Care System recreates near-physiologic conditions ex vivo and includes device variants for lungs, hearts and livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 25 | Jan 1 | TMDX | TransMedics Group, Inc. | TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea. | Closed | -4.2% |
| Sep 8 | Sep 15 | TMDX | TransMedics Group, Inc. | TransMedics delivered robust Q2 revenue (+38% YoY), raised 2025 guidance, received an FDA conditional approval for a key trial (Aug 2025), and shows strong technical momentum with clear near-term catalysts, although ongoing litigation and valuation levels advise cautious position sizing. | Closed | +8.3% |